Reviewer's report

Title: Rizatriptan versus rizatriptan plus rofecoxib versus rizatriptan plus tolfenamic acid in the acute treatment of migraine

Version: 2 Date: 27 May 2004

Reviewer: Hartmut Göbel

Reviewer's report:

General
This is an open study showing that a combination of rizatriptan and NSAR is more effective than rizatriptan as mono-therapy. The study is limited by the open design and small number of subject. The advantage is a within-subject design. As a pilot study the paper contents important informations for further controlled studies

Major Compulsory Revisions (that the author must respond to before a decision on publication can be reached)

Minor Essential Revisions (such as missing labels on figures, or the wrong use of a term, which the author can be trusted to correct)

Discretionary Revisions (which the author can choose to ignore)

What next?: Accept without revision

Level of interest: An article whose findings are important to those with closely related research interests

Quality of written English: Acceptable

Statistical review: No